Previous studies have shown that modulating tissue NAD+ concentrations can influence the metastatic properties of breast cancer cells [74] but whether this is mediated by SIRT1 (NAD+ is the co-substrate for SIRT1 catalysis) has yet to be investigated. This evidence concerns the gene SIRT1 and breast carcinoma.